- Home
- CFB vs OPT Comparison
CFB vs OPT Comparison
Compare CFB & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFB
- OPT
- Stock Information
- Founded
- CFB 2007
- OPT 1984
- Country
- CFB United States
- OPT Australia
- Employees
- CFB N/A
- OPT N/A
- Industry
- CFB Major Banks
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CFB Finance
- OPT Health Care
- Exchange
- CFB Nasdaq
- OPT Nasdaq
- Market Cap
- CFB 751.6M
- OPT 855.6M
- IPO Year
- CFB 2019
- OPT 2020
- Fundamental
- Price
- CFB $16.14
- OPT $5.09
- Analyst Decision
- CFB Strong Buy
- OPT Strong Buy
- Analyst Count
- CFB 3
- OPT 1
- Target Price
- CFB $19.33
- OPT $12.00
- AVG Volume (30 Days)
- CFB 232.5K
- OPT 40.1K
- Earning Date
- CFB 04-14-2025
- OPT 03-03-2025
- Dividend Yield
- CFB N/A
- OPT N/A
- EPS Growth
- CFB 16.42
- OPT N/A
- EPS
- CFB 1.56
- OPT N/A
- Revenue
- CFB $250,664,000.00
- OPT $261,859.00
- Revenue This Year
- CFB N/A
- OPT N/A
- Revenue Next Year
- CFB $4.74
- OPT $46,864.26
- P/E Ratio
- CFB $10.35
- OPT N/A
- Revenue Growth
- CFB 8.51
- OPT N/A
- 52 Week Low
- CFB $10.64
- OPT $1.79
- 52 Week High
- CFB $19.22
- OPT $6.30
- Technical
- Relative Strength Index (RSI)
- CFB 49.96
- OPT 53.99
- Support Level
- CFB $16.17
- OPT $4.77
- Resistance Level
- CFB $16.89
- OPT $5.46
- Average True Range (ATR)
- CFB 0.54
- OPT 0.32
- MACD
- CFB -0.01
- OPT -0.11
- Stochastic Oscillator
- CFB 49.07
- OPT 20.60
About CFB CrossFirst Bankshares Inc.
CrossFirst Bankshares Inc is engaged in providing banking and financial services to businesses, business owners, professionals, and professional networks. The services offered by the company includes Checking accounts, Savings accounts, Personal Loans, International Banking, Business Loans, and Treasury services. The company generates revenue from interest income and fees on loans and interest earned from its marketable securities portfolio.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.